Castle Biosciences, Inc. (NASDAQ:CSTL), a diagnostic company with a robust gross profit margin of 82% and strong balance sheet showing more cash than debt, has entered into a collaboration and license agreement with SciBase Holding AB to develop a diagnostic test that predicts flares in patients with atopic dermatitis, according to a press release statement issued Monday.
The collaboration will utilize SciBase’s Electrical Impedance Spectroscopy technology, which includes both desktop and point-of-care instruments. The companies aim to create a test that can predict flares before symptoms appear, allowing patients to initiate rescue treatment plans earlier. Castle Biosciences, currently valued at $541 million.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.